PriceTargets.com logo

Adamas Pharmaceuticals - ADMS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$8.22 As of 11/24/2021 01:00 AM ET
+0 (0.00%)
Get New Adamas Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADMS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Adamas Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.22.

This chart shows the closing price for ADMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Adamas Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/22/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/17/2021Northland SecuritiesDowngradeOutperform ➝ Market Perform$8.50
10/12/2021HC WainwrightDowngradeBuy ➝ Neutral$10.00 ➝ $9.10
10/12/2021Piper SandlerDowngradeOverweight ➝ Neutral$7.00 ➝ $8.00
10/11/2021Leerink PartnersDowngradeOutperform ➝ Market Perform
10/11/2021JMP SecuritiesDowngradeMarket Outperform ➝ Market Perform
10/11/2021William BlairDowngradeOutperform ➝ Market Perform
8/27/2021William BlairReiterated RatingBuy
8/10/2021HC WainwrightReiterated RatingBuy$10.00
6/7/2021HC WainwrightBoost TargetBuy$10.00 ➝ $12.00
5/13/2021Leerink PartnersReiterated RatingBuy$6.00
2/2/2021HC WainwrightBoost TargetBuy$10.00 ➝ $12.00
1/28/2021Northland SecuritiesBoost Target$7.50 ➝ $12.50
1/14/2021Needham & Company LLCReiterated RatingHold
8/10/2020William BlairReiterated RatingBuy
8/7/2020Needham & Company LLCReiterated RatingNeutral ➝ Hold
8/7/2020Northland SecuritiesReiterated RatingBuy$7.50
6/5/2020HC WainwrightReiterated RatingBuy$10.00
6/5/2020William BlairReiterated RatingBuy
(Data available from 5/22/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Adamas Pharmaceuticals logo
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Read More

Today's Range

Now: $8.22
Low: $8.22
High: $8.22

50 Day Range

MA: $8.17
Low: $7.97
High: $8.23

52 Week Range

Now: $8.22
Low: $4.02
High: $9.15

Volume

N/A

Average Volume

692,487 shs

Market Capitalization

$376.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Adamas Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Adamas Pharmaceuticals in the last twelve months: Wall Street Zen.
View the latest analyst ratings for ADMS.

What is the current price target for Adamas Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Adamas Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Adamas Pharmaceuticals in the next year.
View the latest price targets for ADMS.

What is the current consensus analyst rating for Adamas Pharmaceuticals?

Adamas Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADMS.

What other companies compete with Adamas Pharmaceuticals?

Other companies that are similar to Adamas Pharmaceuticals include Liquidia, Janux Therapeutics, Evotec, Structure Therapeutics and ARS Pharmaceuticals. Learn More about companies similar to Adamas Pharmaceuticals.

How do I contact Adamas Pharmaceuticals' investor relations team?

Adamas Pharmaceuticals' physical mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company's listed phone number is (510) 450-3500 and its investor relations email address is [email protected]. The official website for Adamas Pharmaceuticals is www.adamaspharma.com. Learn More about contacing Adamas Pharmaceuticals investor relations.